171 GSK Annual Report 2018 Strategic report Governance and remuneration Financial statements Investor information 21.
Other investments continued GSK has elected to designate the majority of its equity investments as measured at fair value through other comprehensive income FVTOCI.
The most significant of these investments held at 31 December 2018 were in Theravance Biopharma, Inc. in which the Group holds 17.4% of the common stock, Orchard in which the group holds 14.5% and 23andMe in which the Group holds 14.5%.
These investments had a fair value at 31 December 2018 of 194 million 2017 199 million, 154 million and 229 million respectively.
No other investment is individually material.
The other investments include equity stakes in companies with which GSK has research collaborations and in companies which provide access to biotechnology developments of potential interest.
Information on dividends received from investments measured at FVTOCI is provided in Note 7 Other operating income expense.
On disposal of equity investments measured at FVTOCI, the accumulated fair value movements are reclassified from the fair value reserve to retained earnings.
Investments with a fair value of 148 million were disposed of during the year.
The cumulative gain on these investments after tax was 56 million.
Certain other investments, such as investments in funds with limited lives, are measured at fair value through profit or loss FVTPL.
The cumulative gain loss on investments measured at FVTPL which were disposed of during the year was nil.
The fair value of these investments on derecognition was nil.
In 2017, prior to the Groups implementation of IFRS 9, the cumulative fair value movements, based on average cost for shares acquired at different times, for all other investments disposed of during the period were reclassified from the fair value reserve to the income statement.
The impairment losses recorded above for the prior year were recognised in the income statement within Other operating income, together with amounts reclassified from the fair value reserve on recognition of the impairments.
These impairments resulted from prolonged or significant declines in the fair value of the equity investments below acquisition cost.
The carrying value at 31 December 2017 of Other investments which had been impaired was as follows: 2017 m Original cost 475 Cumulative impairments recognised in the income statement 283 Subsequent fair value increases 210 Carrying value at 31 December 2017 402 Cumulative impairments on those Other investments designated as measured at FVTOCI under IFRS 9 were transferred from retained earnings to the fair value reserve on 1 January 2018 on adoption of IFRS 9.
Other non-current assets 2018 2017 m m Amounts receivable under insurance contracts 675 648 Pension schemes in surplus 760 538 Other receivables 141 227 1,576 1,413 Amounts receivable under insurance contacts are held at fair value through profit or loss.
In regards to the other receivables of 141 million, 89 million is classified as financial assets of which 41 million is classified as fair value through profit or loss.
Of the remaining balance of 48 million, the expected credit loss allowance was immaterial at 31 December 2018.
